Monograph: Optimizing Care for Patients with Heart Failure: How PAs Can Help Improve Outcomes
This activity outlines therapies used in treatment and evidence-based guidelines for the management of patients with heart failure. Also available,Clinical Dialogue and eCase Challenge - Optimizing Care for Patients with Heart Failure: How PAs Can Help Improve Outcomes

Optimizing Care for Patients with Heart Failure: How PAs Can Help Improve Outcomes

Lawrence Herman, MPA, PA-C, DFAAPA; Daniel Thibodeau, MHP, PA-C, DFAAPA; Todd Nolen, MPA, PA-C

Heart failure (HF) exacts a significant toll on affected individuals, placing them at risk of morbidity, diminished functional abilities, lesser quality of life, and mortality. The prevalence of HF is expected to continue to increase as the U.S. population ages, underscoring the need for PAs to stay abreast of current treatments, the respective roles of these therapies in HF management as specified in evidence-based guidelines, and the management of comorbidities. As newer therapies have become available, it is particularly important that PAs be knowledgeable about these treatments and the latest recommendations concerning their use. Despite progress in HF management, deficiencies remain, as reflected in persistently high rates of readmission. Given all these considerations, it is imperative that PAs be prepared to meet the challenges of HF treatment.   

Educational Objectives

At the conclusion of this activity, the PA should be better able to:
  • Apply knowledge of therapies used in the treatment of heart failure when managing patients.
  • Review current evidence-based guidelines for the management of chronic heart failure and recent updates addressing the incorporation of newer pharmacotherapies.
  • Use appropriate management strategies when addressing comorbidities in patients with chronic heart failure.

Accreditation Statement


This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid through November 30, 2019.

Responsibility Statement

AAPA takes responsibility for the content, quality, and scientific integrity of this CME activity.

Disclosure Policy Statement

It is the policy of AAPA to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member has with the commercial interest of any commercial product discussed in an educational presentation. The participating faculty reported the following:

Faculty

Lawrence Herman, MPA, PA-C, DFAAPA
Moderator
Associate Program Director, Adjunct Professor
University of Texas Medical Branch - Galveston
School of Medicine, PA Studies
Galveston, TX
Disclosure – Consultant: Novo Nordisk; Speaker’s Bureau: Novo Nordisk

Daniel Thibodeau, MHP, PA-C, DFAAPA
Associate Professor
Director Clinical Education Recruitment and Support
Eastern Virginia Medical School
Norfolk, VA
No relationship with any commercial interests whose products or services may be mentioned during this presentation.

Todd Nolen, MPA, PA-C
Cardiopulmonary Critical Care and Nuclear Cardiology
Dallas Veterans Affairs
North Texas Health Care System
Dallas, TX

Clinical Faculty, CONNECT-HF Heart Failure Trial
Duke Clinical Research Institute
Durham, NC
No relationship with any commercial interests whose products or services may be mentioned during this presentation.

Activity Planners

Michael Speidel, Jennifer Gregg, PhD, and Joanne Jeffers, Medical Logix, LLC have no relationship with any commercial interests whose products or services may be mentioned during this presentation.

AAPA Staff Activity Planners

Daniel Pace has no relationship with any commercial interests whose products or services may be mentioned during this presentation.

Off-Label/Unapproved Product(s) Discussion

There are no references to off-label/unapproved uses of products in this program.

Disclaimer

The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients.

Acknowledgement of Commercial Support

Supported by an independent educational grant from Novartis Pharmaceuticals Corporation

AAPA offers no returns or refunds for online CME activities purchased through the AAPA store. All sales are final.


Type:     Internet Activity (Enduring Material)
134 Registered Users